Human albumin

Hypersensitivity. Heart failure with normal or increased intravascular volume, severe anaemia. Dilution with sterile water for inj.

Patient with conditions where hypervolaemia and its consequences or haemodilution may increase the risk of adverse reactions (e.g. hypertension, oesophageal varices, pulmonary oedema, haemorrhagic diathesis, renal and post-renal anuria); severe traumatic brain injury, low cardiac reserve. Postoperative or injured patient. Avoid rapid infusion in patients with history of CV disease. Not recommended as a source of supplemental caloric protein in patients requiring nutritional support. Renal and hepatic impairment. Children. Pregnancy and lactation. Monitoring Parameters Regularly monitor electrolyte levels, haematocrit or Hb levels, urine output, central venous pressure, pulmonary artery wedge pressure, arterial blood pressure and pulse rate. Closely observe for heart failure and pulmonary oedema during administration.

Significant: Severe allergic or anaphylactic reactions, coagulation abnormality, electrolyte imbalance (large volume replacement); cardiac, respiratory, or renal failure; increased intracranial pressure; hypervolaemia. Cardiac disorders: Tachycardia, bradycardia. Gastrointestinal disorders: Vomiting, nausea. General disorders and administration site conditions: Chills, fever, chest tightness. Nervous system disorders: Headache, tremor, dizziness. Psychiatric disorders: Confusional state. Respiratory, thoracic and mediastinal disorders: Stridor, bronchospasm, dyspnoea. Skin and subcutaneous tissue disorders: Rash erythematosus, angioneurotic oedema, hyperhidrosis, urticaria. Vascular disorders: Hypertension, hypotension, flushing.

Intravenous & other sterile solutions

B05AA01 - albumin ; Belongs to the class of blood substitutes and plasma protein fractions. Used as blood substitutes.